To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Overview

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with Penpulimab in patients with relapsed and refractory lymphoma

Full Title of Study: “Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Relapsed or Refractory Lymphoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2023

Interventions

  • Drug: TQB2618 injection
    • TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)
  • Drug: Penpulimab injection
    • Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)

Arms, Groups and Cohorts

  • Experimental: TQB2618 injction+penpulimab injection
    • TQB2618 injection with penpulimab injection, 21 days as a treatment cycle

Clinical Trial Outcome Measures

Primary Measures

  • dose limiting toxicity/DLT
    • Time Frame: From the first injection up to 3 weeks
    • The relevant adverse reactions occurred within the first cycle
  • recommended phase II dose/RP2D
    • Time Frame: From the first injection up to 6 weeks
    • The dose of TQB2618 injection which is recommended to use during phase II clinical trial
  • Overall response rate (ORR) based on 2014 Lugano
    • Time Frame: From the first injection up to 96 weeks
    • Percentage of participants achieving complete response (CR) and partial response (PR).

Secondary Measures

  • complete remission rate/CRR
    • Time Frame: From the first injection up to 96 weeks
    • Percentage of participants achieving complete response
  • Disease control rate/DCR
    • Time Frame: From the first injection up to 96 weeks
    • Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).
  • Duration of Response (DOR)
    • Time Frame: From the first injection up to 120 weeks
    • The time when the participants first achieved CR or PR to disease progression or death from any cause.
  • Progression-free survival (PFS)
    • Time Frame: Up to 96 weeks
    • PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause. cause. cause. PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
  • Overall survival/OS
    • Time Frame: From date of randomization until the death from any cause, assessed up to 120 weeks
    • OS defined as the time from randomization until the death from any cause
  • Peak time/Tmax
    • Time Frame: Cycle 1 day 1 Before administration, 30 minuets,4,8,24,48,144,312 hours after minuets, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before and 30 minutes after administration.each cycle 21 days
    • The time to peak concentration
  • Peak concentration (Cmax)
    • Time Frame: Cycle 1 day 1 Before administration, 30 minuets,4,8,24,48,144,312 hours after minuets, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before and 30 minutes after administration.(each cycle 21 days)
    • Maximum plasma drug concentration
  • Half-life /T1/2
    • Time Frame: Cycle 1 day 1 Before administration, 30 minuets,4,8,24,48,144,312 hours after minuets, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before and 30 minutes after administration.(each cycle 21 days)
    • The time it takes for the drug’s concentration in the body to drop by half
  • Receptor Occupancy/RO
    • Time Frame: Cycle 1 day 1, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before administration and 30 minutes after administration and the day of disease progression(each cycle 21 days)
    • The extent to which antibody drugs occupy cell surface targets
  • Incidence of Anti-Drug antibody and neutralizing antibodies
    • Time Frame: Cycle 1 day 1, Cycle 2 day 1, Cycle 4 day 1, Cycle 8 day 1,before administration and 30, 90 days after the last administration(each cycle 21 days)
    • The incidence of anti-drug antibody and neutralizing antibodies after administration of TQB2618 and penpulimab
  • Adverse event rate
    • Time Frame: Baseline up to 96 weeks
    • The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

Participating in This Clinical Trial

Inclusion Criteria

  • 1 Subjects with pathologically proven with relapsed or refractory lymphoma and with disease progression during or after the last treatment or no objective response confirmed after adequate treatment. – 2 Cohort 1: Subjects with Classical Hodgkin lymphoma (cHL) who had previously received at least twice systemic therapy and are resistant to PD-1 or PD-L1. – 3 Cohort 2: Subjects with B lymphocyte non-Hodgkin lymphoma (B-NHL) who had previously received at least twice systemic therapy containing anti-CD20-targeted therapy. – 4 Cohort 3:Subjects with T lymphocyte non-Hodgkin lymphoma (T-NHL) who had previously received at least one systemic therapy. – 5 Subjects with measurable lesions as defined by Lugano2014. – 6 Aged 18-75 years ; Eastern Cooperative Oncology Group (ECOG) score:0 ~ 1; Expected survival ≥3 months. – 7 Laboratory indicators meet the requirements. – 8 Subjects voluntarily joined the study and signed the informed consent form. – 9 Non-pregnant or non-breastfeeding women; Negative pregnancy subjects. Exclusion Criteria:

  • 1 Subjects who have developed or is currently suffering from other malignancies within 3 years, with the exception of cured skin basal cell carcinoma and cervical carcinoma in situ. – 2 Subjects who have not recovered to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 due to the adverse event of prior therapy. – 3 Subjects with significant surgery or significant traumatic injury within 28 days before first injection (excluding needle biopsy or endoscopic biopsy). – 4 Subjects with long-term unhealed wounds or fractures. – 5 Subjects with the high risk of bleeding or bleeding history or subjects with bleeding event (≥Common Terminology Criteria for Adverse Events Grade 3) within 4 weeks before first injection. – 6 Subjects with arterial/venous thrombosis within 6 months. – 7 Subjects with a history of psychotropic substance abuse who cannot be withdrawn or have mental disorders. – 8 Subjects with any severe and/or uncontrolled disease. – 9 subjects with lymphoma originating from Central Nervous System, high-grade B-cell lymphoma or hemophagocytic syndrome during screening period. – 10 Subjects with violating Central Nervous System (CNS) . – 11 Subjects with allogeneic hematopoietic stem cell transplantation. – 12 Subjects with autologous hematopoietic stem cell transplantation or Chimeric Antigen Receptor T-Cell Immunotherapy(CAR-T) within 3 months before first injection. – 13 Subjects with other factors that might cause the study to be terminated halfway per the judgement of the investigator.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Tongyu Lin, Doctor, 18108243837, tongyulin@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.